R. S. Herbst Et Al. , "Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042," Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO) , vol.30, Geneva, Switzerland, 2019
Herbst, R. S. Et Al. 2019. Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042. Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO) , (Geneva, Switzerland).
Herbst, R. S., Lopes, G., Kowalski, D. M., Kasahara, K., Wu, Y., De Castro, G., ... Cho, B. C.(2019). Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042 . Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland
Herbst, R. Et Al. "Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042," Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 2019
Herbst, R. S. Et Al. "Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042." Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO) , Geneva, Switzerland, 2019
Herbst, R. S. Et Al. (2019) . "Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042." Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO) , Geneva, Switzerland.
@conferencepaper{conferencepaper, author={R. S. Herbst Et Al. }, title={Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042}, congress name={Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO)}, city={Geneva}, country={Switzerland}, year={2019}}